| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/30/2005 | WO2005058286A1 Sustained release torsemide dosage forms |
| 06/30/2005 | WO2005058281A1 Hydroxysteroid dehydrogenase inhibitors adsorbed on hydrophilic carriers |
| 06/30/2005 | WO2005058280A2 Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure |
| 06/30/2005 | WO2005058277A1 Injectable composition |
| 06/30/2005 | WO2005058275A2 Ingestible capsules containing ethanol |
| 06/30/2005 | WO2005058273A1 Compositions containing methylthioadenosine (mta) and topical use thereof |
| 06/30/2005 | WO2005058255A1 Composition for improving skin, hair and coat health containing flavanones |
| 06/30/2005 | WO2005058248A2 A method of treating hiv infection in atazanavir resistant patients using a combination of atazanavir and another protease inhibitor |
| 06/30/2005 | WO2005058246A2 Method for preparing radiolabeled thymidine |
| 06/30/2005 | WO2005058245A2 Synthetic process |
| 06/30/2005 | WO2005058238A2 Antimicrobial composition |
| 06/30/2005 | WO2005058235A2 Methods using sulodexide for the treatment of bladder disease |
| 06/30/2005 | WO2005058231A2 Rifamycin analogs and uses thereof |
| 06/30/2005 | WO2005058230A2 Topical use of halosalicylic acid derivatives |
| 06/30/2005 | WO2005058064A1 Astaxanthin-containing pet foods |
| 06/30/2005 | WO2005058024A2 Method of treating fish and crustaceans with a tellurium based immunomodulator |
| 06/30/2005 | WO2005058002A2 High efficiency fullerene-based radical scavengers |
| 06/30/2005 | WO2005051328A3 Amelioration of macular degeneration and other ophthalmic diseases |
| 06/30/2005 | WO2005041921A3 Dry powder compositions for inhalation therapy comprising calcium stearate, medical devices therefor |
| 06/30/2005 | WO2005040758A8 Use of pirfenidone in therapeutic regimens |
| 06/30/2005 | WO2005039589A3 Cftr channel modulators |
| 06/30/2005 | WO2005039563A3 Use of neurokinin antagonists in the treatment of urinary incontinence |
| 06/30/2005 | WO2005039548A3 Use of effectors of glutaminyl and glutamate cyclases |
| 06/30/2005 | WO2005037287A8 Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7) en-2-yl)alkyl]phosphonic acid and derivatives |
| 06/30/2005 | WO2005037227A3 Selective cox-2 inhibitors |
| 06/30/2005 | WO2005034952A3 Isoxazole and isothiazole compounds useful in the treatment of inflammation |
| 06/30/2005 | WO2005034932A3 Amino acid based compositions for the treatment of pathological conditions distinguished by insufficient mitochondrial function |
| 06/30/2005 | WO2005033113A3 Indole derivatives |
| 06/30/2005 | WO2005033099A3 Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
| 06/30/2005 | WO2005033049A3 METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF |
| 06/30/2005 | WO2005032493A8 Amide compounds as ion channel ligands and uses thereof |
| 06/30/2005 | WO2005032484A3 Alkoxy substituted imidazoquinolines |
| 06/30/2005 | WO2005032343A3 Hedgehog signaling in prostate regeneration neoplasia and metastasis |
| 06/30/2005 | WO2005030148A3 Tetrahydroindolone derivatives for treatment of neurological conditions |
| 06/30/2005 | WO2005028617A3 Antisense inhibition of laminin-8 expression to inhibit human gliomas |
| 06/30/2005 | WO2005027886A3 Methods of preventing or treating recurrence of myocardial infarction |
| 06/30/2005 | WO2005027881A3 Stable quinapril compositions |
| 06/30/2005 | WO2005027838A3 Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives |
| 06/30/2005 | WO2005025574A3 PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. |
| 06/30/2005 | WO2005023896A3 Purified polyoxypropylene/polyoxyethylene copolymers and method of preparing the same |
| 06/30/2005 | WO2005021548A3 Substituted 8-heteroaryl xanthines |
| 06/30/2005 | WO2005020958A3 Aerosol delivery of curcumin |
| 06/30/2005 | WO2005018560A3 Methods of reducing risk of infection from pathogens |
| 06/30/2005 | WO2005017098A3 AMPHIPATHIC AND POLYCATIONIC COMPOUNDS FOR DELIVERING siRNA |
| 06/30/2005 | WO2005016277A3 Arylsulfonamidobenzylic compounds |
| 06/30/2005 | WO2005016242A8 Synthetic process for trans-aminocyclohexyl ether compounds |
| 06/30/2005 | WO2005007143A3 Use of makrolides and ketolides for the treatment of tuberculosis |
| 06/30/2005 | WO2005004926A8 Dendritic cell infiltrativity activating composition and immune activator |
| 06/30/2005 | WO2005002573A3 Methods for using modulators of proline-rich tyrosine kinase 2 |
| 06/30/2005 | WO2004110392A3 Compositions and methods for treating coronavirus infection and sars |
| 06/30/2005 | WO2004108080A3 Method for treating diseases using hsp90-inhibiting agents in combination with immunosuppressants |
| 06/30/2005 | WO2004100960A8 Anti-inflammatory phosphonate compounds |
| 06/30/2005 | WO2004096236A3 Immunomodulator phosphonate conjugates |
| 06/30/2005 | WO2004093788A3 Desmoglein 4 is a novel gene involved in hair growth |
| 06/30/2005 | WO2004089926A3 Genipin derivatives and uses thereof |
| 06/30/2005 | WO2004087649A3 Benodiazepine spirohydantoin cgrp receptor antagonists |
| 06/30/2005 | WO2004087148A9 Remedy and/or preventive for lung diseases |
| 06/30/2005 | WO2004085388A3 Cyclic protein tyrosine kinase inhibitors |
| 06/30/2005 | WO2004084809A3 Neuroprotective macrocylic compounds and methods for their use |
| 06/30/2005 | WO2004080343A3 Compositions and methods for use of alginate dural sealants |
| 06/30/2005 | WO2004078213A9 Composition for target substance introduction and method of target substance introduction |
| 06/30/2005 | WO2004076640A3 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same |
| 06/30/2005 | WO2004065614A3 Suppression of cytotoxic protein conformers |
| 06/30/2005 | WO2004047829A8 New synergistic combination comprising roflumilast and formoterol |
| 06/30/2005 | WO2004046159A8 Antiviral nucleoside derivatives |
| 06/30/2005 | WO2004043352A8 Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases |
| 06/30/2005 | WO2004035611A3 Peptides binding the phosphatase 2a protein and polynucleotides encoding same |
| 06/30/2005 | WO2004018999A3 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 06/30/2005 | WO2004017942A8 Inhalation compositions with high drug ratios |
| 06/30/2005 | WO2004017918A9 Method of preparing dry powder inhalation compositions |
| 06/30/2005 | WO2003101403A3 Use of peroxisome proliferator activated receptor (ppar)-gamma ligands as a treatment for pituitary tumors and associated conditions, such as cushing's syndrome |
| 06/30/2005 | WO2002058698A8 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 06/30/2005 | US20050144656 treating fruitflies (Drosophila melanogaster) with medium containing strychnine, pentylenetetrazol, tetraethylammonium chloride, lithium carbonate and nicotine, then crossing to produce inheritable changes in locomotor behavior |
| 06/30/2005 | US20050143788 Treatment of female fertility conditions through modulation of the autonomic nervous system |
| 06/30/2005 | US20050143738 Laterally insertable interspinous process implant |
| 06/30/2005 | US20050143596 Process for producing triterpene derivative |
| 06/30/2005 | US20050143583 Processes for the preparation of substituted isoxazoles and 2-isoxazolines |
| 06/30/2005 | US20050143578 Compounds and methods |
| 06/30/2005 | US20050143475 Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury |
| 06/30/2005 | US20050143473 Methods for treating allergy |
| 06/30/2005 | US20050143470 therapeutic treatment of Porcine Respiratory Disease Complex (PRDC) in pigs and Bovine Respiratory Syndrome (BRS) in calves; oral treatment; veterinary medicine |
| 06/30/2005 | US20050143468 administering amfenac or nepafenac; ophthalmic disorder, proliferative diabetic retinopathy, vision defects |
| 06/30/2005 | US20050143467 Adjust fatty acid oxidation; stimulant carnitine palmitoly transferase |
| 06/30/2005 | US20050143466 drug delivery to infiltrate into spaces in skin; exposing skin to light energy to cause photosensitizing agent to become photodynamically activated; sebaceous gland disorder, sebum secretion, skin disorders |
| 06/30/2005 | US20050143465 secretions is derived from around the uropygial gland of an avian; attractants for treating bird weight loss, during transportation to eliminate their tension; animal extracts for treating bird's behavioral disorder, nervous system disorder |
| 06/30/2005 | US20050143464 With low side effects, which rapidly stimulate early insulin secretion and suppress blood glucose increase only at mealtimes; antidiabetic agent; triterpene acids or alcohols with picene ring; corosolic acids; oleanene acids; ursenoic acids; banaba plant extracts |
| 06/30/2005 | US20050143463 endothelial cell proliferation; alkyl-substituted fatty acid with immunosuppressants as cyclosporin A, rapamycin or FK506; angiofibroma, neovascularisation, arteriovenous malformations, rheumatoid arthritis, lupus, connective tissue disorders, Osler-Weber syndrome, atherosclerotic plaques, psoriasis |
| 06/30/2005 | US20050143462 Opening a sultone ring with a nucleophile to produce propanedisulfonic acids and salts, 3-amino-1-propanesulfonic acid and 1,3-propanedisulfonic acid disodium salt with increased purity; byproduct inhibition; treating amyloidosis |
| 06/30/2005 | US20050143461 inhibiting transmission of sexually transmitted diseases by applying a mixture of suramin sodium and a surfactant; including other active microbiocides, fungicides, viricides, bactericides, antifertility agents |
| 06/30/2005 | US20050143460 Dosage forms has pH of greater than about 7 to less than 9, storage stability, contains pravastatin sodium and excipient; treating cardiovascular disorders related to hyperlipidemia, coronary event; analysis to determine the presence of impurity |
| 06/30/2005 | US20050143458 Use of isovaleryl L-carnitine for the preparation of a medicament for the prevention and cure of fractures |
| 06/30/2005 | US20050143456 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments |
| 06/30/2005 | US20050143455 such as (4-methyl-trans-cyclohexane-1,2-diamine)-oxalatoplatinum |
| 06/30/2005 | US20050143453 Selective preventing and therapeutic agents for progressive lesion after organic damage |
| 06/30/2005 | US20050143451 Use of parthenolide to inhibit cancer |
| 06/30/2005 | US20050143450 6-methyl-1,3,8-trichlorodibenzofuran; aryl hydrocarbon receptor (AhR) agonist; chemotherapy for benign and malignant prostatic hypertrophy (BPH and MPH), androgen responsive and nonresponsive neoplasm |
| 06/30/2005 | US20050143449 Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
| 06/30/2005 | US20050143448 CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel antifibrogenic pathway in the liver |
| 06/30/2005 | US20050143447 Mixing at least one nonaqueous, pharmaceutically acceptable solvent and a taxane compound |
| 06/30/2005 | US20050143446 Compounds for use as antigrowth agents or antitumor agents and with solvents |